Connecting via Winsock to STN

STN STRUCTURE SEARCH (REGISTRY/CAPLUS)
CLAIMS 1-3

Welcome to STN International! Enter x:x

LOGINID:SSPTAJMN1626

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	AUG 06	CAS REGISTRY enhanced with new experimental property tags
NEWS 3	AUG 06	FSTA enhanced with new thesaurus edition
NEWS 4	AUG 13	CA/CAplus enhanced with additional kind codes for granted patents
NEWS 5	AUG 20	CA/CAplus enhanced with CAS indexing in pre-1907 records
NEWS 6	AUG 27	Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS 7	AUG 27	USPATOLD now available on STN
NEWS 8	AUG 28	CAS REGISTRY enhanced with additional experimental spectral property data
NEWS 9	SEP 07	STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS 10	SEP 13	FORIS renamed to SOFIS
NEWS 11	SEP 13	INPADOCDB enhanced with monthly SDI frequency
NEWS 12	SEP 17	CA/CAplus enhanced with printed CA page images from 1967-1998
NEWS 13	SEP 17	CAplus coverage extended to include traditional medicine patents
NEWS 14	SEP 24	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS 15	OCT 02	CA/CAplus enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS 16	OCT 19	BEILSTEIN updated with new compounds
NEWS 17	NOV 15	Derwent Indian patent publication number format enhanced
NEWS 18	NOV 19	WPIX enhanced with XML display format
NEWS 19	NOV 30	ICSD reloaded with enhancements
NEWS 20	DEC 04	LINPADOCDB now available on STN
NEWS 21	DEC 14	BEILSTEIN pricing structure to change
NEWS 22	DEC 17	USPATOLD added to additional database clusters
NEWS 23	DEC 17	IMSDRUGCONF removed from database clusters and STN
NEWS 24	DEC 17	DGENE now includes more than 10 million sequences
NEWS 25	DEC 17	TOXCENTER enhanced with 2008 MeSH vocabulary in MEDLINE segment
NEWS 26	DEC 17	MEDLINE and LMEDLINE updated with 2008 MeSH vocabulary
NEWS 27	DEC 17	CA/CAplus enhanced with new custom IPC display formats
NEWS 28	DEC 17	STN Viewer enhanced with full-text patent content from USPATOLD
NEWS 29	JAN 02	STN pricing information for 2008 now available
NEWS 30	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances
NEWS 31	JAN 28	USPATFULL, USPAT2, and USPATOLD enhanced with new

```
                  custom IPC display formats
 NEWS 32  JAN 28  MARPAT searching enhanced
 NEWS 33  JAN 28  USGENE now provides USPTO sequence data within 3 days
                  of publication
 NEWS 34  JAN 28  TOXCENTER enhanced with reloaded MEDLINE segment
 NEWS 35  JAN 28  MEDLINE and LMEDLINE reloaded with enhancements
 NEWS 36  FEB 08  STN Express, Version 8.3, now available
 NEWS 37  FEB 20  PCI now available as a replacement to DPCI


 NEWS EXPRESS FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3,
              AND CURRENT DISCOVER FILE IS DATED 24 JANUARY 2008

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 10:22:52 ON 21 FEB 2008

=> FIL REG
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.21       0.21

FILE 'REGISTRY' ENTERED AT 10:23:17 ON 21 FEB 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   20 FEB 2008  HIGHEST RN 1004854-20-9
DICTIONARY FILE UPDATES:  20 FEB 2008  HIGHEST RN 1004854-20-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:
```

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10528982\1.str





chain nodes :
10 11 12 13 14 15 16 18 20 21
ring nodes :
1 2 3 4 5 6 7 8 9
chain bonds :
7-13 9-10 10-11 10-12 13-14 13-20 13-21 14-15 14-16 16-18
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9
exact/norm bonds :
5-7 7-8 7-13 8-9 10-11 10-12 14-15 16-18
exact bonds :
6-9 9-10 13-14 13-20 13-21 14-16
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 :

G1:H,Ak

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 18:CLASS 20:CLASS
21:CLASS

L1 STRUCTURE UPLOADED

=> D
L1 HAS NO ANSWERS
L1 STR



G1 H,Ak

Structure attributes must be viewed using STN Express query preparation.

=> S L1
SAMPLE SEARCH INITIATED 10:23:31 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 122 TO ITERATE

100.0% PROCESSED 122 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 1778 TO 3102

```
PROJECTED ANSWERS:                0 TO        0

L2             0 SEA SSS SAM L1

=> D SCAN
L2 HAS NO ANSWERS
```

```
=> S L1 FULL
FULL SEARCH INITIATED 10:23:52 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -     2670 TO ITERATE

100.0% PROCESSED     2670 ITERATIONS                                 6 ANSWERS
SEARCH TIME: 00.00.01

L3             6 SEA SSS FUL L1
```

```
=> D SCAN
```

```
=> D HIS

     (FILE 'HOME' ENTERED AT 10:22:52 ON 21 FEB 2008)

     FILE 'REGISTRY' ENTERED AT 10:23:17 ON 21 FEB 2008
L1              STRUCTURE UPLOADED
L2            0 S L1
L3            6 S L1 FULL

=> FIL CAPLUS
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                               178.82     179.03

FILE 'CAPLUS' ENTERED AT 10:24:29 ON 21 FEB 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 21 Feb 2008  VOL 148 ISS 8
FILE LAST UPDATED: 20 Feb 2008  (20080220/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> S L3
L4            8 L3

=> D IBIB ABS HITSTR TOT
```

L4 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:619587 CAPLUS
DOCUMENT NUMBER: 147:31554
TITLE: Transition metal compound, ligand system, catalyst system and process for preparing polyolefins
INVENTOR(S): Mihan, Shahram; Bildstein, Benno; Solchinger, Alexander; Koelling, Lars
PATENT ASSIGNEE(S): Basell Polyolefine G.m.b.H., Germany
SOURCE: PCT Int. Appl., 61pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007062790	A2	20070607	WO 2006-EP11343	20061127
WO 2007062790	A3	20070719		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
DE 102005057559	A1	20070531	DE 2005-102005057559	20051130
PRIORITY APPLN. INFO.:			DE 2005-102005057559	20051130
			US 2005-753272P P	20051222

OTHER SOURCE(S): MARPAT 147:31554
GI

L4 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



I

AB The present invention relates to transition metal compds. of the formula I; where M is an element of group 3, 4, 5, 6, 7, 8, 9 or 10 of the Periodic Table of the Elements or the lanthanide's, the radicals X are identical or different and are each an organic or inorg. radical, with two radicals X also being able to be joined to one another to form a divalent radical, is 1 , 2, 3 or 4, L1 is an organic or inorg. uncharged ligand, is an integer from 0 to 4, R1 is an organic radical having from 1 to 40 carbon atoms, R2 is hydrogen or an organic radical having from 1 to 40 carbon atoms, or R1 and R2 together form a divalent organic group T1 which has from 2 to 40 carbon atoms and together with the atoms connecting its ends forms a monocyclic or polycyclic ring system which may in turn be substituted and may comprise one or more further heteroatoms selected from the group consisting of the elements O, S, Se, Te, N, P and. As in the ring system, R3 is hydrogen or an organic radical having from 1 to 40 carbon atoms, R4 is hydrogen or an organic radical having from 1 to 40 carbon atoms, or R3 and R4 together form a divalent organic group T2 which has from 2 to 40 carbon atoms and together with the atoms connecting its ends forms a monocyclic or polycyclic ring system which may in turn be substituted and may comprise one or more heteroatoms selected from the group consisting of the elements O, S, Se, Te, N, P and As in the ring system, R5 is an uncharged or neg. charged organic radical which has from 1 to 40 carbon atoms and may comprise a heteroatom selected from the group consisting of the elements N, O, P, S, As and Sb, and m is an integer from 1 to 10. Ligand systems having such a substitution pattern, ligand systems comprising at least one of the transition metal compds. according to the invention, a process for preparing

L4 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
polyolefins by polymn. or copolymn. of at least one olefin in the presence of at least one of the catalyst systems according to the invention and the use of the ligand systems according to the invention for prepg. transition metal compds.org. radical which has from 1 to 40 carbon atoms and may comprise a heteroatom selected from the group consisting of the elements N, O, P, S, As and Sb, and m is an integer from 1 to 10, ligand systems having such a substitution pattern, ligand systems comprising at least one of the transition metal compds. according to the invention, a process for prepg. polyolefins by polymn. or copolymn. of at least one olefin in the presence of at least one of the catalyst systems according to the invention and the use of the ligand systems according to the invention for prepg. transition metal compds.
IT 938072-97-0P
RL: IMF (Industrial manufacture); RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)
(building block; preparation of transition metal complexes of iminomethylpyrazole derivs. for catalysts for production of polyolefins)
RN 938072-97-0 CAPLUS
CN 1H-Indazole-3-carboxaldehyde, 1-(3,3-dimethyl-2-oxobutyl)- (CA INDEX NAME)



L4 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:589276 CAPLUS
DOCUMENT NUMBER: 147:31548
TITLE: Transition metal compound, iminomethylpyrazole derivative ligand system, catalyst system and procedure for the production of polyolefins
PATENT ASSIGNEE(S): Basell Polyolefine G.m.b.H., Germany
SOURCE: Ger. Offen., 41pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 102005057559	A1	20070531	DE 2005-102005057559	20051130
WO 2007062790	A2	20070607	WO 2006-EP11343	20061127
WO 2007062790	A3	20070719		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
PRIORITY APPLN. INFO.:			DE 2005-102005057559A	20051130
			US 2005-753272P P	20051222

OTHER SOURCE(S): MARPAT 147:31548
GI

I



AB The invention concerns transition metal compds. I, where M an element of Group 3, 4, 5, 6, 7, 8, 9 or 10 or a lanthanide, X is and an organic or

L4 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
inorg. group, whereby two X groups can be linked also with one another to a divalent group, n is 1, 2, 3 or 4, L1 is an org. or inorg. neutral ligand, h is 0 to 4, R1, R2, R3, R4 are org. groups with 1 to 40 carbon atoms or R1 and R2 and R3 and R4 together form one divalent org. group T1 with 2 to 40 carbon atoms, which forms a (substituted) mono- or polycyclic ring system optionally contg. heteroatoms selected from S, Se, Te, N, P and As, R5 is a neutral or neg. charged group contg. 1-40 carbon atoms and optionally ≥1 heteroatom selected from O, S, Se, Te, N, P and As, and m is 1-10 which are highly active catalysts for polymn. of olefins. A typical catalyst was manufd. by redn. of indazole-3-carboxylic acid, oxidn. of the intermediate alc., reaction of the resulting aldehyde with 2-picolyl chloride, reaction of the resulting aldehyde with 2,6-diisopropylaniline, and complexation of the resulting ligand with FeCl2.
IT 938072-97-0P
RL: IMF (Industrial manufacture); RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)
(ligand precursor; transition metal complexes of iminomethylpyrazole derivs. for catalysts for production of polyolefins)
RN 938072-97-0 CAPLUS
CN 1H-Indazole-3-carboxaldehyde, 1-(3,3-dimethyl-2-oxobutyl)- (CA INDEX NAME)



L4 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:144056 CAPLUS
DOCUMENT NUMBER: 146:229363
TITLE: Preparation of oxazine derivatives as Ep4 receptor agonists and antiglaucoma agents
INVENTOR(S): Colucci, John; Han, Yongxin; Farand, Julie A.
PATENT ASSIGNEE(S): Merck Frosst Canada Ltd., Can.
SOURCE: PCT Int. Appl., 54pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007014462	A1	20070208	WO 2006-CA1254	20060728

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2005-705120P P 20050803

OTHER SOURCE(S): MARPAT 146:229363
GI

L4 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



I



II

AB This invention relates to potent selective agonists of the EP4 subtype of prostaglandin E2 receptors I, wherein R represents (CH2)xCOOR3, (CH2)nC3-10 cycloalkyl; -(CH2)nC3-10 heterocyclyl, (CH2)nC5-10 aryl, said cycloalkyl, heterocyclyl, and aryl substituted with R2; provided that when R is -(CH2)nC3-10 heterocyclyl it does not represent thienyl; R1 independently represents hydrogen, C1-6-alkyl, halogen, CF3, aryl, said aryl optionally substituted with 1-3 groups of halogen, C1-6 alkyl, CF3, or N(R4)2; R2 represents COOR3 or a carboxylic acid isostere; R3 and R4 independently represent H, or C1-6-alkyl; n represents 0-3; x is 2-5, their use or a formulation thereof in the treatment of glaucoma and other conditions, which are related to elevated intraocular pressure in the eye of a patient. This invention further relates to the use of the compds. of this invention for mediating the bone modeling and remodeling processes of the osteoblasts and osteoclasts. Thus, oxazine II was prepared and tested in rats as Ep4 receptor agonist in osteoblastic cell lines and in bone tissue. Effects of an EP4 agonist on intraocular pressure in rabbits and monkeys, are reported. Title compds. showed improved ocular tolerability in animal species such as rabbits and cynomolgus monkeys. The activity range of the compds. of this invention for bone use is between 0.01 and 100,000 nM. Stable expression of prostanoid receptors in the human embryonic kidney (HEK) 293 (EBNA) cell line is reported.
IT 691899-65-7, 1-(3-Isobutyryl-6-methoxy-1H-indazol-1-yl)-3,3-dimethylbutan-2-one 866465-62-5, 1-[3-(3-Hydroxypropanoyl)-6-methoxy-1H-indazol-1-yl]-3,3-dimethylbutan-2-one
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of oxazine derivs. as Ep4 receptor agonists antiglaucoma agents)
RN 691899-65-7 CAPLUS

L4 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
CN 2-Butanone, 1-[6-methoxy-3-(2-methyl-1-oxopropyl)-1H-indazol-1-yl]-3,3-dimethyl- (CA INDEX NAME)



RN 866465-62-5 CAPLUS
CN 2-Butanone, 1-[3-(3-hydroxy-1-oxopropyl)-6-methoxy-1H-indazol-1-yl]-3,3-dimethyl- (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:143969 CAPLUS
DOCUMENT NUMBER: 146:229362
TITLE: Preparation of oxazine derivatives as Ep4 receptor agonists and antiglaucoma agents
INVENTOR(S): Colucci, John; Han, Yongxin; Farand, Julie A.
PATENT ASSIGNEE(S): Merck Frosst Canada Ltd., Can.
SOURCE: PCT Int. Appl., 47pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007014454	A1	20070208	WO 2006-CA1243	20060728

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2005-705124P P 20050803

OTHER SOURCE(S): MARPAT 146:229362
GI

L4 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



I



II

AB This invention relates to potent selective agonists of the EP4 subtype of prostaglandin E2 receptors I, wherein R1 independently represents hydrogen, C1-6 alkyl, halogen, CF3, aryl, said aryl optionally substituted with 1 to 3 groups of halogen, C1-6 alkyl, CF3, substituted amine; R2 represents H, or halogen; R3 represents COOR or carboxylic acid isostere; n represents 0-3; their use or a formulation thereof in the treatment of glaucoma and other conditions, which are related to elevated intraocular pressure in the eye of a patient. This invention further relates to the use of the compds. of this invention for mediating the bone modeling and remodeling processes of the osteoblasts and osteoclasts. Thus, oxazine II was prepared and tested in rats as EP4 receptor agonist in osteoblastic cell lines and in bone tissue. Effects of an EP4 agonist on intraocular pressure in rabbits and monkeys, are reported. Title compds. showed improved ocular tolerability in animal species such as rabbits and cynomolgus monkeys.

IT 691899-65-7, 1-(3-Isobutyryl-6-methoxy-1H-indazol-1-yl)-3,3-dimethylbutan-2-one 866465-62-5, 1-[3-(3-Hydroxypropanoyl)-6-methoxy-1H-indazol-1-yl]-3,3-dimethylbutan-2-one
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of oxazine derivs. as EP4 receptor agonists and antiglaucoma

L4 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
agents)

RN 691899-65-7 CAPLUS
CN 2-Butanone, 1-[6-methoxy-3-(2-methyl-1-oxopropyl)-1H-indazol-1-yl]-3,3-dimethyl- (CA INDEX NAME)



RN 866465-62-5 CAPLUS
CN 2-Butanone, 1-[3-(3-hydroxy-1-oxopropyl)-6-methoxy-1H-indazol-1-yl]-3,3-dimethyl- (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:164871 CAPLUS
DOCUMENT NUMBER: 144:254122
TITLE: Preparation of indazole derivatives and ophthalmic compositions for treating ocular hypertension
INVENTOR(S): Doherty, James B.; Shen, Dong-Ming
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 44 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006020003	A2	20060223	WO 2005-US25136	20050715
WO 2006020003	A3	20060831		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

AU 2005274972	A1	20060223	AU 2005-274972	20050715
CA 2574078	A1	20060223	CA 2005-2574078	20050715
EP 1771170	A2	20070411	EP 2005-771451	20050715

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR

CN 1988903	A	20070627	CN 2005-80024510	20050715
US 2008032951	A1	20080207	US 2006-630172	20061219
IN 2006CN04793	A	20071005	IN 2006-CN4793	20061229

PRIORITY APPLN. INFO.: US 2004-589444P P 20040720
WO 2005-US25136 W 20050715

OTHER SOURCE(S): CASREACT 144:254122; MARPAT 144:254122
GI

L4 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



I



II

AB Title compds. I [M, M1, M2 = CH or N; Z = N or C, when Z = N then the bond
between Y and Z is a single bond and between X and Y resp. represents CR1=N, CR1=CR1a, CR1a=CR1, or N=CR1, and when Z = C then X = O or S, Y represents CR1 and the bond between Y and Z is a double bond; R4 and R5 independently = H, OH, alkoxy, etc.; Q = unsatd. phosphonate derivative or
substituted carbonyl alkyl derivative; R1 = OH, alkoxy,, unsatd. phosphonate
derivative, etc.; R1a = H, (un)substituted alkyl, cycloalkyl, etc.], and their
pharmaceutically acceptable salts, are prepared and disclosed as potassium
channel blockers suitable for ophthalmic compns. fore treatment of glaucoma and other conditions which leads to elevated intraoccular pressure in the eye of a patient. Thus, e.g., II was prepared by amidation
of (3-isobutyryl-6-methoxy-1H-indazol-1-yl)acetic acid (preparation given) with
di-n-butylamine. In assays for evaluating ability to block potassium channels, I was determined to possess IC50's in the range of about 1nM to about
20 μM. This invention also relates to the use of such compds. to provide a neuroprotective effect to the eye of mammalian species, particularly humans.

IT 691899-65-7P 877144-26-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of indazole derivs. and ophthalmic compns. thereof for treating
ocular hypertension)

RN 691899-65-7 CAPLUS
CN 2-Butanone, 1-[6-methoxy-3-(2-methyl-1-oxopropyl)-1H-indazol-1-yl]-3,3-dimethyl- (CA INDEX NAME)

L4 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 877144-26-8 CAPLUS
CN 2-Butanone, 1-[3-(2-bromo-2-methyl-1-oxopropyl)-6-methoxy-1H-indazol-1-yl]-3,3-dimethyl- (CA INDEX NAME)



L4 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:1289303 CAPLUS
DOCUMENT NUMBER: 144:36257
TITLE: Preparation of substituted benzoic acid and analogs as
EP4 receptor agonists for treatment of glaucoma and related diseases
INVENTOR(S): Belley, Michel; Colucci, John; Girard, Mario; Han, Yongxin; Lacombe, Patrick
PATENT ASSIGNEE(S): Merck Frosst Canada Ltd., Can.
SOURCE: PCT Int. Appl., 80 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005116010	A1	20051208	WO 2005-CA773	20050520

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2004-574653P P 20040526

OTHER SOURCE(S): MARPAT 144:36257
GI

L4 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



I



II

AB Title compds. I [Z1 = CW1, N; W1, X, W = H, amino, halo; Y = H, halo, alkoxy, etc.; R1-2 = H, halo, alkyl, etc.; R3 = R1, OH, etc.; Q = carboxy,
tetrazolyl, etc.; Ar1 = Ph, pyridinyl, thienyl, etc.; Ar2 = benzoxadiazolyl, Ph, pyridyl, etc.] are prepared For instance, II is prepared
in 4 steps from 3-bromo-5-chloro-2-hydroxybenzaldehyde, 3-methoxybenzyl bromide, 4-bromobenzonitrile and azidotributyltin. II has a binding affinity for the EP4 subtype of prostaglandin E2 receptor of 2.0 nM. I are useful for the treatment of glaucoma and other conditions which are related to elevated intraocular pressure in the eye of a patient. I are also used for mediating the bone modeling and remodeling processes of osteoblasts and osteoclasts.

IT 691899-65-7, 1-(3-Isobutyryl-6-methoxy-1H-indazol-1-yl)-3,3-dimethylbutan-2-one 691901-12-9, 1-(3-Isobutyryl-6-methoxy-1H-indazol-1-yl)butan-2-one 866465-62-5, 1-[3-(3-Hydroxypropanoyl)-6-methoxy-1H-indazol-1-yl]-3,3-dimethylbutan-2-one
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(agonists of EP4 receptor subtype of PGE2 receptors and their use for treatment of glaucoma, other conditions and for mediating bone modeling
and remodeling processes of osteoblasts and osteoclasts)

RN 691899-65-7 CAPLUS
CN 2-Butanone, 1-[6-methoxy-3-(2-methyl-1-oxopropyl)-1H-indazol-1-yl]-3,3-dimethyl- (CA INDEX NAME)

L4 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 691901-12-9 CAPLUS
CN 2-Butanone, 1-[6-methoxy-3-(2-methyl-1-oxopropyl)-1H-indazol-1-yl]- (CA INDEX NAME)



RN 866465-62-5 CAPLUS
CN 2-Butanone, 1-[3-(3-hydroxy-1-oxopropyl)-6-methoxy-1H-indazol-1-yl]-3,3-dimethyl- (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:1106800 CAPLUS
DOCUMENT NUMBER: 143:387049
TITLE: Preparation of disubstituted piperidinones, oxazinanones, thiazinanones, and morpholinones as EP4 receptor agonist for treatment of ocular and bone disorders
INVENTOR(S): Billot, Xavier; Colucci, John; Han, Yongxin; Wilson, Marie-claire; Young, Robert N.
PATENT ASSIGNEE(S): Can.
SOURCE: U.S. Pat. Appl. Publ., 30 pp., Division of U.S. Ser. No. 297,257.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005227969	A1	20051013	US 2005-146992	20050607
US 7238710	B2	20070703		
US 2004198701	A1	20041007	US 2004-797257	20040310
US 7053085	B2	20060530		
BR 2004008690	A	20060328	BR 2004-8690	20040326
IN 2005DN03925	A	20070824	IN 2005-DN3925	20050902
IN 2005DN03928	A	20070824	IN 2005-DN3928	20050902
MX 2005PA10189	A	20060222	MX 2005-PA10189	20050923
NO 2005004951	A	20051222	NO 2005-4951	20051025
PRIORITY APPLN. INFO.:			US 2003-457700P	P 20030326
			US 2004-797257	A3 20040310
			WO 2004-CA471	W 20040326

OTHER SOURCE(S): MARPAT 143:387049
AB This invention relates to potent selective agonists of the EP4 subtype of prostaglandin E2 receptors, their use or a formulation thereof in the treatment of glaucoma and other conditions, which are related to elevated intraocular pressure in the eye of a patient. This invention further relates to the use of the compds. of this invention for mediating the bone modeling and remodeling processes of the osteoblasts and osteoclasts. In particular, this invention relates to a series of 1,6-disubstituted piperidin-2-one, 3,4-disubstituted 1,3-oxazinan-2-one, 3,4-disubstituted 1,3-thiazinan-2-one, and 4,5-disubstituted morpholin-3-one derivs. The compds. of the invention are optionally formulated with other therapeutic agents useful in treating eye disorders or in stimulating bone formation such as β-adrenergic blocking agents, carbonic anhydrase inhibitors, and bisphosphonates. Preparation schemes for the compds. of the invention are disclosed.
IT 691899-65-7, 1-(3-Isobutyryl-6-methoxy-1H-indazol-1-yl)-3,3-dimethylbutan-2-one 691901-12-9, 1-(3-Isobutyryl-6-methoxy-1H-indazol-1-yl)butan-2-one 866465-62-5, 1-[3-(3-Hydroxypropanoyl)-

L4 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
6-methoxy-1H-indazol-1-yl]-3,3-dimethylbutan-2-one
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(addnl. therapeutic agent; prepn. of disubstituted piperidinones, oxazinanones, thiazinanones, and morpholinones as EP4 receptor agonists for treatment of ocular and bone disorders)
RN 691899-65-7 CAPLUS
CN 2-Butanone, 1-[6-methoxy-3-(2-methyl-1-oxopropyl)-1H-indazol-1-yl]-3,3-dimethyl- (CA INDEX NAME)



RN 691901-12-9 CAPLUS
CN 2-Butanone, 1-[6-methoxy-3-(2-methyl-1-oxopropyl)-1H-indazol-1-yl]- (CA INDEX NAME)



RN 866465-62-5 CAPLUS
CN 2-Butanone, 1-[3-(3-hydroxy-1-oxopropyl)-6-methoxy-1H-indazol-1-yl]-3,3-dimethyl- (CA INDEX NAME)



L4 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
REFERENCE COUNT: 44 THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

THESE COMPOUNDS ARE NOT IN THE US PATENTS

L4 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:414645 CAPLUS
DOCUMENT NUMBER: 140:423670
TITLE: Preparation of indazoles as potent potassium channel blockers for treating ocular hypertension
INVENTOR(S): Doherty, James B.; Chen, Meng-Hsin; Liu, Luping; Natarajan, Swaminathan R.; Tynebor, Robert M.
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: U.S. Pat. Appl. Publ., 30 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004097575	A1	20040520	US 2003-684990	20031014
US 7196082	B2	20070327		
TW 250873	B	20060311	TW 2003-92130678	20031103
CA 2505086	A1	20040527	CA 2003-2505086	20031104
WO 2004043932	A1	20040527	WO 2003-US35078	20031104
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
WO 2004043933	A1	20040527	WO 2003-US35080	20031104
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003286884	A1	20040603	AU 2003-286884	20031104
AU 2003287506	A1	20040603	AU 2003-287506	20031104
EP 1562909	A1	20050817	EP 2003-781747	20031104
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003016040	A	20050913	BR 2003-16040	20031104
CN 1708484	A	20051214	CN 2003-80102578	20031104
JP 2006508190	T	20060309	JP 2005-507086	20031104
NZ 539593	A	20061222	NZ 2003-539593	20031104
MX 2005PA04889	A	20050722	MX 2005-PA04889	20050506
NO 2005002751	A	20050607	NO 2005-2751	20050607
US 2006154897	A1	20060713	US 2005-528982	20050815

L4 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
US 2007129418 A1 20070607 US 2006-641212 20061219
IN 2007DN04017 A 20070831 IN 2007-DN4017 20070528
PRIORITY APPLN. INFO.: US 2002-424808P P 20021108
US 2003-500091P P 20030904
US 2003-684990 A 20031014
WO 2003-US35078 W 20031104
WO 2003-US35080 W 20031104
IN 2005-DN1709 A3 20050427

OTHER SOURCE(S): MARPAT 140:423670
GI



AB The title compds. [I; R = H, alkyl; X = (CHR7)p, (CHR7)pCO; Y = CO(CH2)n, CH2, CH(OR); Q = CH, C(alkyl); R2 = H, alkyl, OH, etc.; R3 = H, alkyl, heterocyclyl, etc.; QR2R3 = 3-10 membered carbocyclic or heterocyclic ring, OR; R4, R5 = H, alkoxy, OH, etc.; R6 = H, alkyl, (CH2)n(aryl), etc.;
R7 = H, alkyl, (CH2)nCO2R, (CH2)nNR2; n = 0-3; p = 0-3], useful for the treatment of glaucoma and other conditions which leads to elevated intraocular pressure in the eye of a patient, were prepared Thus, reacting
3-benzoyl-6-methoxyindazole (preparation given) with 1-bromopinacolone in the
presence of NaH in DMF afforded II. The IC50 for block of maxi-K channels
for the compds. I ranged from about 0.5 nM to about 10 μM. This invention also relates to the use of compds. I to provide a neuroprotective effect to the eye of mammalian species, particularly humans. Ophthalmic compns. comprising the compound I is claimed.

IT 691899-65-7P 691901-12-9P 691901-45-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

L4 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
(prepn. of indazoles as potent potassium channel blockers for treating ocular hypertension)

RN 691899-65-7 CAPLUS
CN 2-Butanone, 1-[6-methoxy-3-(2-methyl-1-oxopropyl)-1H-indazol-1-yl]-3,3-dimethyl- (CA INDEX NAME)



RN 691901-12-9 CAPLUS
CN 2-Butanone, 1-[6-methoxy-3-(2-methyl-1-oxopropyl)-1H-indazol-1-yl]- (CA INDEX NAME)



RN 691901-45-8 CAPLUS
CN 2-Butanone, 1-[3-(2,2-dimethyl-1-oxopropyl)-6-methoxy-1H-indazol-1-yl]-3,3-dimethyl- (CA INDEX NAME)



REFERENCE COUNT: 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> FIL REG
COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                     ENTRY    SESSION
FULL ESTIMATED COST                                  45.52     224.55

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)      SINCE FILE      TOTAL
                                                     ENTRY    SESSION
CA SUBSCRIBER PRICE                                  -6.40      -6.40

FILE 'REGISTRY' ENTERED AT 10:27:00 ON 21 FEB 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   20 FEB 2008  HIGHEST RN 1004854-20-9
DICTIONARY FILE UPDATES:  20 FEB 2008  HIGHEST RN 1004854-20-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10528982\2.str
```





chain nodes :
10 11 12 13 14 15 16 20
ring nodes :
1 2 3 4 5 6 7 8 9
chain bonds :
7-13 9-10 10-11 10-12 13-14 13-20 14-15 14-16
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9
exact/norm bonds :
5-7 7-8 7-13 8-9 10-11 10-12 14-15
exact bonds :
6-9 9-10 13-14 13-20 14-16
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 :

G1:H,Ak

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 20:CLASS

L5 STRUCTURE UPLOADED

=> D
L5 HAS NO ANSWERS
L5 STR



BROADER SEARCH

G1 H,Ak

Structure attributes must be viewed using STN Express query preparation.

=> S L5 FULL
FULL SEARCH INITIATED 10:27:15 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 2670 TO ITERATE

100.0% PROCESSED 2670 ITERATIONS 8 ANSWERS
SEARCH TIME: 00.00.01

L6 8 SEA SSS FUL L5

=> D HIS

(FILE 'HOME' ENTERED AT 10:22:52 ON 21 FEB 2008)

```
     FILE 'REGISTRY' ENTERED AT 10:23:17 ON 21 FEB 2008
L1              STRUCTURE UPLOADED
L2            0 S L1
L3            6 S L1 FULL

     FILE 'CAPLUS' ENTERED AT 10:24:29 ON 21 FEB 2008
L4            8 S L3

     FILE 'REGISTRY' ENTERED AT 10:27:00 ON 21 FEB 2008
L5              STRUCTURE UPLOADED
L6            8 S L5 FULL

=> FIL CAPLUS
COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                               178.36     402.91

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)      SINCE FILE      TOTAL
                                                   ENTRY    SESSION
CA SUBSCRIBER PRICE                                 0.00      -6.40

FILE 'CAPLUS' ENTERED AT 10:27:39 ON 21 FEB 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 21 Feb 2008  VOL 148 ISS 8
FILE LAST UPDATED: 20 Feb 2008  (20080220/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> S L6
L7            8 L6

=> S L7 OR L4
L8            8 L7 OR L4

=> FIL STNGUIDE
COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
```

SAME DOCUMENTS AS THE FIRST SEARCH